Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations - PubMed (original) (raw)
Review
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Benedikt Fischer et al. Am J Public Health. 2017 Aug.
Erratum in
- ERRATUM.
[No authors listed] [No authors listed] Am J Public Health. 2018 May;108(5):e2. doi: 10.2105/AJPH.2017.303818e. Am J Public Health. 2018. PMID: 31329668 Free PMC article.
Abstract
Background: Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors that are modifiable by the user, evidence-based Lower-Risk Cannabis Use Guidelines (LRCUG)-akin to similar guidelines in other health fields-offer a valuable, targeted prevention tool to improve public health outcomes.
Objectives: To systematically review, update, and quality-grade evidence on behavioral factors determining adverse health outcomes from cannabis that may be modifiable by the user, and translate this evidence into revised LRCUG as a public health intervention tool based on an expert consensus process.
Search methods: We used pertinent medical search terms and structured search strategies, to search MEDLINE, EMBASE, PsycINFO, Cochrane Library databases, and reference lists primarily for systematic reviews and meta-analyses, and additional evidence on modifiable risk factors for adverse health outcomes from cannabis use.
Selection criteria: We included studies if they focused on potentially modifiable behavior-based factors for risks or harms for health from cannabis use, and excluded studies if cannabis use was assessed for therapeutic purposes.
Data collection and analysis: We screened the titles and abstracts of all studies identified by the search strategy and assessed the full texts of all potentially eligible studies for inclusion; 2 of the authors independently extracted the data of all studies included in this review. We created Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow-charts for each of the topical searches. Subsequently, we summarized the evidence by behavioral factor topic, quality-graded it by following standard (Grading of Recommendations Assessment, Development, and Evaluation; GRADE) criteria, and translated it into the LRCUG recommendations by the author expert collective on the basis of an iterative consensus process.
Main results: For most recommendations, there was at least "substantial" (i.e., good-quality) evidence. We developed 10 major recommendations for lower-risk use: (1) the most effective way to avoid cannabis use-related health risks is abstinence, (2) avoid early age initiation of cannabis use (i.e., definitively before the age of 16 years), (3) choose low-potency tetrahydrocannabinol (THC) or balanced THC-to-cannabidiol (CBD)-ratio cannabis products, (4) abstain from using synthetic cannabinoids, (5) avoid combusted cannabis inhalation and give preference to nonsmoking use methods, (6) avoid deep or other risky inhalation practices, (7) avoid high-frequency (e.g., daily or near-daily) cannabis use, (8) abstain from cannabis-impaired driving, (9) populations at higher risk for cannabis use-related health problems should avoid use altogether, and (10) avoid combining previously mentioned risk behaviors (e.g., early initiation and high-frequency use).
Authors' conclusions: Evidence indicates that a substantial extent of the risk of adverse health outcomes from cannabis use may be reduced by informed behavioral choices among users. The evidence-based LRCUG serve as a population-level education and intervention tool to inform such user choices toward improved public health outcomes. However, the LRCUG ought to be systematically communicated and supported by key regulation measures (e.g., cannabis product labeling, content regulation) to be effective. All of these measures are concretely possible under emerging legalization regimes, and should be actively implemented by regulatory authorities. The population-level impact of the LRCUG toward reducing cannabis use-related health risks should be evaluated. Public health implications. Cannabis control regimes are evolving, including legalization in North America, with uncertain impacts on public health. Evidence-based LRCUG offer a potentially valuable population-level tool to reduce the risk of adverse health outcomes from cannabis use among (especially young) users in legalization contexts, and hence to contribute to improved public health outcomes.
Comment in
- Fischer et al. Respond.
Fischer B, van den Brink W, Hall W, LeFoll B, Rehm J, Room R. Fischer B, et al. Am J Public Health. 2017 Dec;107(12):e26-e27. doi: 10.2105/AJPH.2017.304147. Am J Public Health. 2017. PMID: 29116834 Free PMC article. No abstract available. - Low-Risk Cannabis Use Is an Oxymoron.
Braillon A. Braillon A. Am J Public Health. 2017 Dec;107(12):e26. doi: 10.2105/AJPH.2017.304146. Am J Public Health. 2017. PMID: 29116835 Free PMC article. No abstract available. - Lower-Risk Cannabis Use Guidelines: Will Users Listen?
Caulkins JP, Kilborn ML. Caulkins JP, et al. Am J Public Health. 2020 Jan;110(1):71-72. doi: 10.2105/AJPH.2019.305420. Am J Public Health. 2020. PMID: 31800288 Free PMC article. No abstract available.
Similar articles
- Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update.
Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Pacula RL, Rehm J, Room R, van den Brink W, Hall W. Fischer B, et al. Int J Drug Policy. 2022 Jan;99:103381. doi: 10.1016/j.drugpo.2021.103381. Epub 2021 Aug 28. Int J Drug Policy. 2022. PMID: 34465496 Review. - Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR, Alston LV, Bolton KA, Whelan J, Reeve E, Wong Shee A, Browne J, Walker T, Versace VL, Allender S, Nichols M, Backholer K, Goodwin N, Lewis S, Dalton H, Prael G, Curtin M, Brooks R, Verdon S, Crockett J, Hodgins G, Walsh S, Lyle DM, Thompson SC, Browne LJ, Knight S, Pit SW, Jones M, Gillam MH, Leach MJ, Gonzalez-Chica DA, Muyambi K, Eshetie T, Tran K, May E, Lieschke G, Parker V, Smith A, Hayes C, Dunlop AJ, Rajappa H, White R, Oakley P, Holliday S. Osborne SR, et al. Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144 - Introducing the evidence-based population health tool of the Lower-Risk Cannabis Use Guidelines to Brazil.
Fischer B, Malta M, Messas G, Ribeiro M. Fischer B, et al. Braz J Psychiatry. 2019 Nov-Dec;41(6):550-555. doi: 10.1590/1516-4446-2018-0239. Braz J Psychiatry. 2019. PMID: 31116260 Free PMC article. - Public sector reforms and their impact on the level of corruption: A systematic review.
Mugellini G, Della Bella S, Colagrossi M, Isenring GL, Killias M. Mugellini G, et al. Campbell Syst Rev. 2021 May 24;17(2):e1173. doi: 10.1002/cl2.1173. eCollection 2021 Jun. Campbell Syst Rev. 2021. PMID: 37131927 Free PMC article. Review.
Cited by
- A Social-Ecological Model for Understanding Cannabis Risks and Promoting Harm Reduction.
Kruger DJ, Bone CC, Kruger JS. Kruger DJ, et al. Am J Public Health. 2024 Nov;114(S8):S628-S630. doi: 10.2105/AJPH.2024.307742. Am J Public Health. 2024. PMID: 39442031 Free PMC article. No abstract available. - Unmet Healthcare Needs and Medical Cannabis Use Among Sexual and Gender Minoritized Adults in a High-Stigma Environment.
Vogel EA, McQuoid J, Romm KF, Kendzor DE, Cohn AM. Vogel EA, et al. J Homosex. 2025 Jan 2;72(1):1-19. doi: 10.1080/00918369.2024.2302427. Epub 2024 Jan 9. J Homosex. 2025. PMID: 38193883 - Life-course Accumulated Cannabis Use and Recent Cannabis-related Problems in the Washington Panel Survey.
Zhu Y, Greenfield TK, Ye Y, Williams E, Kerr WC. Zhu Y, et al. Addict Behav. 2024 May;152:107957. doi: 10.1016/j.addbeh.2024.107957. Epub 2024 Jan 17. Addict Behav. 2024. PMID: 38277992 - Treatment Implications Associated with Cannabis and Tobacco Co-Use.
McClure EA, Rabin RA, Lee DC, Hindocha C. McClure EA, et al. Curr Addict Rep. 2020 Dec;7(4):533-544. doi: 10.1007/s40429-020-00334-8. Epub 2020 Oct 2. Curr Addict Rep. 2020. PMID: 33777645 Free PMC article. - "Guarding their practice": a descriptive study of Canadian nursing policies and education related to medical cannabis.
Balneaves LG, Alraja AA. Balneaves LG, et al. BMC Nurs. 2019 Dec 9;18:66. doi: 10.1186/s12912-019-0390-7. eCollection 2019. BMC Nurs. 2019. PMID: 31827392 Free PMC article.
References
- World Drug Report 2015. Vienna, Austria: United Nations Office on Drugs and Crime; 2015.
- Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012. Ottawa, ON: Health Canada; 2014.
- Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–1391. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials